Taken together, we report a novel triazole, MortaparibMild that targets mortalin and PARP1, causes activation of wild type p53 function in cancer cells and hence warrants further attention for elucidating its mechanisms of action (involving DNA damage, stress, tumor suppressor, metastatic and other signaling pathways), experimental validation of its anticancer activity in laboratory and clinic. This evidence concerns the gene HSPA9 and cancer.